Assertio Therapeutics (ASRT) Stock Statistics & Valuation Metrics

Assertio Therapeutics has a market cap or net worth of $77.46M. The enterprise value is $9.14M.

Assertio Therapeutics has 96,239,624 shares outstanding. The number of shares has decreased by -2.65% in one year.

Assertio Therapeutics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -14.40%.

The current PE Ratio of Assertio Therapeutics is ―. Assertio Therapeutics’s PEG ratio is ―.

In the last 12 months, Assertio Therapeutics had revenue of 124.96M and earned -21.58M in profits. Earnings per share was -0.23.

In the last 12 months, operating cash flow was 18.07M and capital expenditures 0.00, giving a free cash flow of 18.07M billion.

Assertio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Assertio Therapeutics upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).

Assertio Therapeutics as a current ratio of 1.77, with Debt / Equity ratio of 41.85%

In the past 12 months, Assertio Therapeutics has paid 52.00K in taxes.

Assertio Therapeutics EV to EBITDA ratio is -2.95, with an EV/FCF ratio of 2.73.

Assertio Therapeutics has $98.18M in cash and marketable securities with $45.79M in debt, giving a net cash position of -$52.40M billion.

Gross margin is 67.87%, with operating margin of -19.59%, and net profit margin of -17.27%.

The average price target for Assertio Therapeutics is $3.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy